Ypsomed Holding AG
SIX:YPSN

Watchlist Manager
Ypsomed Holding AG Logo
Ypsomed Holding AG
SIX:YPSN
Watchlist
Price: 342.5 CHF -0.15% Market Closed
Market Cap: 4.7B CHF
Have any thoughts about
Ypsomed Holding AG?
Write Note

Net Margin
Ypsomed Holding AG

12.1%
Current
9%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
74.4m
/
Revenue
617.1m

Net Margin Across Competitors

Country CH
Market Cap 4.7B CHF
Net Margin
12%
Country JP
Market Cap 7T JPY
Net Margin
24%
Country CH
Market Cap 38.2B CHF
Net Margin
12%
Country DK
Market Cap 177.1B DKK
Net Margin
19%
Country US
Market Cap 16.3B USD
Net Margin
11%
Country KR
Market Cap 10.3T KRW
Net Margin
-358%
Country CN
Market Cap 51B CNY
Net Margin
42%
Country US
Market Cap 6.7B USD
Net Margin
29%
Country CA
Market Cap 6.3B USD
Net Margin
-8%
Country UK
Market Cap 4.6B GBP
Net Margin
7%
Country US
Market Cap 5.6B USD
Net Margin
9%
No Stocks Found

Ypsomed Holding AG
Glance View

Market Cap
4.7B CHF
Industry
Health Care

Nestled amid the pioneering spirit of the Swiss medical technology landscape, Ypsomed Holding AG emerges as a quintessential player, carving a niche in the diabetes care and injection systems domains. The company’s journey begins in the Ypsomed headquarters in Burgdorf, Switzerland, where innovation meets precision engineering. Ypsomed's focus largely revolves around its development, production, and distribution of self-injection devices and solutions. This Swiss dynamo engages in crafting state-of-the-art insulin pumps, pen injectors, and smart add-on devices that empower users with diabetes to manage their conditions effectively. It combines clinical expertise with intuitive design, ensuring that their diverse clientele—from patients to medical professionals—receive products that blend seamlessly into everyday life. Not resting on insulin delivery alone, Ypsomed also establishes itself in the world of contract manufacturing, catering to global pharmaceutical and biotech companies with their platform technology and customized solutions. Economically vibrant, Ypsomed’s revenue streams are woven intricately from an array of channels. A significant proportion stems from direct sales of its proprietary diabetes care products under their acclaimed mylife™ brand. Here, it garners a loyal customer base through innovations like the YpsoPump® system, effectively capitalizing on the growing demand for user-friendly diabetes management tools. Additionally, Ypsomed capitalizes on partnerships with major healthcare multinationals by providing contract manufacturing services and licensing technologies, expanding its global footprint while tapping into broader markets. As a strategic player, the company continuously invests in research and development to refine its offerings and maintain a competitive edge in the burgeoning medical device market. Through this dynamic blend of cutting-edge technology and strategic alliances, Ypsomed illustrates a sophisticated business model that not only sustains its profitability but furthers its mission to improve the lives of those in need of reliable, advanced diabetes care solutions.

YPSN Intrinsic Value
313.25 CHF
Overvaluation 9%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
74.4m
/
Revenue
617.1m
What is the Net Margin of Ypsomed Holding AG?

Based on Ypsomed Holding AG's most recent financial statements, the company has Net Margin of 12.1%.